These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31311005)

  • 1. How and when to use temozolomide to treat aggressive pituitary tumours.
    Whitelaw BC
    Endocr Relat Cancer; 2019 Aug; 26(9):R545-R552. PubMed ID: 31311005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
    McCormack AI; Wass JA; Grossman AB
    Eur J Clin Invest; 2011 Oct; 41(10):1133-48. PubMed ID: 21496012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.
    Raverot G; Castinetti F; Jouanneau E; Morange I; Figarella-Branger D; Dufour H; Trouillas J; Brue T
    Clin Endocrinol (Oxf); 2012 Jun; 76(6):769-75. PubMed ID: 22404748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How effective is temozolomide for treating pituitary tumours and when should it be used?
    Halevy C; Whitelaw BC
    Pituitary; 2017 Apr; 20(2):261-266. PubMed ID: 27581836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
    Lizzul L; Lombardi G; Barbot M; Ceccato F; Gardiman MP; Regazzo D; Bellu L; Mazza E; Losa M; Scaroni C
    Pituitary; 2020 Aug; 23(4):359-366. PubMed ID: 32232709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of temozolomide in the treatment of aggressive pituitary tumors.
    Liu JK; Patel J; Eloy JA
    J Clin Neurosci; 2015 Jun; 22(6):923-9. PubMed ID: 25772801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.
    McCormack AI; McDonald KL; Gill AJ; Clark SJ; Burt MG; Campbell KA; Braund WJ; Little NS; Cook RJ; Grossman AB; Robinson BG; Clifton-Bligh RJ
    Clin Endocrinol (Oxf); 2009 Aug; 71(2):226-33. PubMed ID: 19067722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas.
    Minniti G; Paolini S; Rea MLJ; Isidori A; Scaringi C; Russo I; Osti MF; Cavallo L; Esposito V
    J Neurooncol; 2020 Aug; 149(1):123-130. PubMed ID: 32632895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
    Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
    J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
    Losa M; Mazza E; Terreni MR; McCormack A; Gill AJ; Motta M; Cangi MG; Talarico A; Mortini P; Reni M
    Eur J Endocrinol; 2010 Dec; 163(6):843-51. PubMed ID: 20870708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.
    Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Horvath E; Rotondo F; Kovacs K
    Hormones (Athens); 2009; 8(4):303-6. PubMed ID: 20045804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update.
    Syro LV; Rotondo F; Ortiz LD; Kovacs K
    Endocr Relat Cancer; 2018 Aug; 25(8):T159-T169. PubMed ID: 29535142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide therapy for aggressive pituitary tumours - current understanding and future perspectives.
    Burman P; Lamb L; McCormack A
    Rev Endocr Metab Disord; 2020 Jun; 21(2):263-276. PubMed ID: 32147777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
    Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide in aggressive pituitary tumours and pituitary carcinomas.
    McCormack A
    Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101713. PubMed ID: 36274026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide.
    Bengtsson D; Schrøder HD; Berinder K; Maiter D; Hoybye C; Ragnarsson O; Feldt-Rasmussen U; Krogh Rasmussen Å; van der Lely A; Petersson M; Johannsson G; Andersen M; Burman P
    Endocrine; 2018 Dec; 62(3):737-739. PubMed ID: 30246233
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
    Lamas C; Cámara R; Fajardo C; Remon-Ruiz P; Biagetti B; Guerrero-Pérez F; Araujo-Castro M; Mora M; Hanzu F; Iglesias P; García-Centeno R; Soto A
    Front Endocrinol (Lausanne); 2023; 14():1204206. PubMed ID: 37720528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is MGMT the best marker to predict response of temozolomide in aggressive pituitary tumors? Alternative markers and prospective treatment modalities.
    Kontogeorgos G; Thodou E
    Hormones (Athens); 2019 Dec; 18(4):333-337. PubMed ID: 31721137
    [No Abstract]   [Full Text] [Related]  

  • 19. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
    Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M
    Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.
    Micko ASG; Wöhrer A; Höftberger R; Vila G; Marosi C; Knosp E; Wolfsberger S
    Pituitary; 2017 Dec; 20(6):643-653. PubMed ID: 28900805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.